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ABSTRACT
BACKGROUND: Despite the proven effectiveness of antiplatelet and anticoagula-
tion treatment for atrial fibrillation (AF), their use has been suboptimal in practice,
particularly in rural areas of Australia.
OBJECTIVE: The aim of this srudy was to describe medication use in the man-
agement of AF in elderly hospitalized patients with comorbid congestive heart failure
(CHF).
METHODS: The hospital records of patients with a diagnosis of AF and CHF
were reviewed in a rural Australian medical center. All the patients were hospitalized
because of significant systolic ventricular dysfunction. The collected data included
age, sex, weight, presenting symptoms of AF, and principle diagnosis on admission;
medical history; and history of smoking and alcohol consumption. Electrocardiogram
before hospital discharge was also retrieved from patient's medical records and was
analyzed by the investigators. Cardiovascular and noncardiovascular drugs adminis-
tered during the hospital stay and at discharge were also documented. Comparison of
antiarrhythmic and anticoagulant drugs was made between patients who had AF
while hospitalized and those who had a history of AF but were in sinus rhythm while
hospitalized. When patients had ~2 moderate risk factors (eg, age ~75 years, hyper-
tension, CHF, left ventricular ejection fraction :0;35%, diabetes mellirus) or ~1 high
risk factor (eg, previous stroke, transient ischemic attack or embolism, mitral valve
stenosis, or prosthetic heart valve), they were defined as being eligible for anticoagula-
tion treatment.
RESULTS: One hundred forty patients (74 men, 66 women; mean {SD} age,
77.1 [6.9} years; all were white) had a diagnosis of AF and were selected for the study.
Of these, 92 patients (65.7%) (47 women, 45 men; mean [SD} age, 77.4 [9.2} years)
had continuous AF and 48 patients (34.3%) (29 men, 19 women; mean [SD} age,
76.3 [l2.4} years) had a history of AF but were in sinus rhythm at admission and
discharge. The most commonly used antiarrhythmic drug was digoxin, which was
prescribed significantly more frequently in the AF group than in the history of AF
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group (50 [54.3%} vs 14 [29.2%}; P < 0.01). Amiodarone was prescribed signifi-
cantly less frequently in the continuous AF group than in the group with a history of
AF (7 [7.6%} vs 19 [39.6%}; P < 0.01). There was no significant between-group
difference in the use of ~-blockers (26 [28.3%} vs 19 [39.6%}), verapamilldiltiazem
(9 [9.8%} vs 3 [6.3%}), or sotalol (2 [2.2%} vs 4 [8.3%}). The mean (SD) resting
heart rate for the 140 study patients was 91 (27) bpm. The mean resting heart rate
for the patients with AF was significantly higher at admission than at discharge
(97 [28} vs 79 [l9} bpm; P < 0.01). Of the 110 patients who were eligible for
anticoagulation treatment, 64 (58.2%) were prescribed warfarin at discharge. Eligible
patients not receiving oral warfarin were significantly older than those who did receive
warfarin (79.7 [9.0} vs 75.8 [9.0} years; P = 0.02).
CONCLUSIONS: In these elderly hospitalized Australian patients with AF and
CHF, digoxin, ~-blockers, and amiodarone were the most commonly used anti-
arrhythmic drugs. Anticoagulation treatment was prescribed in -60% of these patients.
(Curr Ther Res Clin Exp. 2008;69:514-524) © 2008 Excerpta Medica Inc.
KEY WORDS: atrial fibrillation, heart failure, rate control, antiarrhythmic drugs,
anticoagulation.
INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia among patients with conges-
tive heart failure (CHF).1 AF has been shown to be an independent risk factor for
mortality in the general population and particularly in patients with ischemic heart
disease and/or heart failure. 2,3
The current therapeutic strategies for AF include ventricular rate control, mainte-
nance of sinus rhythm, and prevention of major complications, such as stroke.v?
Major rate control medications include ~-blockers, digoxin, and nondihydropyridine
calcium channel blockers (eg, verapamil or diltiazern)." Prevention of stroke in AF
patients is usually achieved by the long-term use of antiplatelet or anticoagulation
drugs (eg, aspirin or warfarin).s-12 Warfarin has been reported to be more effective
than aspirin in preventing cardioembolic stroke.l>
The use of anticoagulation treatment in patients with AF varies considerably.
A retrospective analysis of hospitalized patients in an Australian teaching hospital
showed that only one third of the patients with chronic or paroxysmal AF with high
risk for stroke received warfarin, with almost one quarter receiving no antithrombotic
agent. 14 In a large-scale European srudy published in 2005 involving 5333 AF pa-
tients (1751 [32.8%} of whom had heart failure), oral anticoagulation therapy was
used in 898 patients (80%) with persistent AF and in 1134 (76%) of those with per-
manent AF.l5 In that srudy, oral anticoagulation therapy was prescribed to 744 of the
1509 patients (49.3%) with paroxysmal AF (347 [l9.8%} with heart failure).
Despite the proven effectiveness of these antiplatelet and anticoagulation drugs,
their use has been suboptimal in practice,12,16,17 particularly in rural areas in Austra-
lia.1S The aim of the current srudy was to describe the management of a population
of elderly hospitalized patients with both CHF and AF in a rural Australian medical
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center. Specifically, we sought to determine what medications and strategies were used
and how successful the strategies were in achieving adequate rate control for AF.
We also examined what proportion of patients, without evident contraindications for
anticoagulation, received warfarin for stroke prophylaxis.
PATIENTS AND METHODS
The human ethics committees of Charles Sturt University (Wagga Wagga, Australia)
(protocol number 2006/031) and the Greater Southern Area Health Service (New
South Wales, Australia) (protocol number 2005/20) approved this study. Because this
was a retrospective analysis of records and all extracted data were deidentified, no
written consent was required from patients.
The management data for patients with AF and CHF were retrospectively collected
from Wagga Wagga Base Hospital (Wagga Wagga, Australia), a teaching hospital and
a referral center with a population of -120,000 in New Sourh Wales. Patients with a
primary diagnosis of CHF on admission and discharge who were hospitalized between
January 2003 and 2005 were first identified using International Classification of Diseases,
Ninth Revision codes.l? Patients aged ::::65 years with electrocardiogram (ECG) evidence
of AF at the time of the hospitalization or a documented history of AF were selected
for further analysis.
Patients with AF identified during hospitalization on baseline ECG, any time dur-
ing the hospital stay, or at the time of discharge were considered to be in the continu-
ous AF group. Those with a history of paroxysmal or persistent/permanent AF but no
AF during hospitalization or at the time of discharge were considered to be in the
group with a history of AF who were currently in sinus rhythm. The diagnosis was
confirmed using admission and discharge ECGs. The diagnosis of AF was based on
previous documentation of ECG contained in patients' medical records.
The collected data included age, sex, weight, presenting symptoms of AF, and
principle diagnosis on admission. Patients' medical history and history of smoking
and alcohol consumption were also collected. Clinical examination results included
blood pressure and heart rate (on the day of hospital discharge), temperature, respira-
tory rate, and oxygen saturation. ECG records before hospital discharge were also
retrieved from patients' medical charts and analyzed by the investigators. Cardio-
vascular and noncardiovascular drugs administered during the hospital stay and at
discharge were also documented. The medications taken prior to hospitalization and
their changes during hospitalization were also reviewed by the investigators.
Adequate rate control for AF was defined as a resting heart rate >60 and ::::80 bpm.f
Hypertension was defined as blood pressure ::::140/90 mm Hg (in patients aged
::::65 years) or ~130/85 mm Hg (in patients aged <65 years or with diaberesj.f"
Bradycardia was defined as a resting heart rate <60 bpm and hypotension as blood pres-
sure <90/60 mm Hg. Risk factors for stroke were assessed according to the 2006
American College of Cardiology/American Heart Association/European Society of Car-
diology guidelines.s! When patients had ~2 moderate-risk factors (eg, age ::::75 years,
hypertension, CHF, left ventricular ejection fraction ::;;35%, or diabetes mellitus) or
~1 high-risk factor (eg, previous stroke, transient ischemic attack or embolism, mitral
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valve stenosis, or prosthetic heart valve), they were defined as being eligible for anti-
coagulation treatment.
STATISTICAL ANALYSIS
Data were expressed as mean (SD) . The t test was used to compare the changes in
heart rate on hospitalization and at discharge within the same group. Categoric data
were analyzed using the X2 test. Analysis of variance was used to compare age, hospital
stay, heart rate, and blood pressure between patients with continuous AF and those
with a history of AF but currently in sinus rhythm. P < 0.05 was considered statisti-
cally significant.
RESULTS
GENERAL FINDINGS
The hospital records of 417 patients with a primary diagnosis ofCHF were reviewed.
Among these patients, 140 (33 .6%) (74 men, 66 women; mean [SD} age, 77.1 [6.9} years;
all were white) had a diagnosis of AF and were selected for this study. Of these patients,
92 (65 .7%) (47 women, 45 men; mean [SD} age, 77.4 [9 .2} years) had continuous AF and
48 (34.3 %) (29 men, 19 women; mean [SD} age , 76.3 [l2.4} years) had a history of AF
but were in sinus rhythm on admission and at discharge. The characteristics of these
patients are shown in Table I. The mean heart rate of patients with AF was significantly
higher than in the patients with a history of AF (97 [28} vs 71 [l4} bpm; P < 0 .01).
Diastolic blood pressure in the continuous AF group was also significantly higher than
in the group with a history of AF (76.2 [l7.7} vs 71.6 [l4.7} mm Hg; P < 0.01).
MEDICATION USE
The average duration of hospitalization of the patients was 6.4 days (Table I).
Among the 140 patients, 81 (57 .9 %) were treated with angiotensin-converting
enzyme inhibitors/angiotensin II receptor blockers, 64 (45.8%) with digoxin,
45 (32 .1 %) with ~-blockers, and 26 (18.6%) with amiodarone (Table II). The use of
cardiovascular medications was similar between the 2 groups. However, a signifi-
cantly greater percentage of patients with a history of AF than patients with continu-
ous AF were treated with amiodarone (19/48 [39.6%} vs 7/92 (7.6%} patients; P <
0.01). In contrast, a significantly greater percentage of patients with continuous AF
than those with a history of AF were treated with digoxin monotherapy (50/92 [54.3%}
vs 14/48 [29.2%}; P < 0.01).
Combination treatment with digoxin and ~-blockers was prescribed to a similar
percentage of patients with AF and those with a history of AF (13.0% [l2/92} vs
10.4% [5I4B}) . The combination of digoxin and amiodarone was also prescribed to a
similar percentage of patients with AF compared with those with a history of AF
(3.3 % O} vs 8.3% [4}).
Seven patients (7 .6 %) with continuous AF were prescribed amiodarone at dis-
charge. One patient (1.1 %) with AF was receiving a combination of metoprolol and
verapamil at discharge. His blood pressure was 154/90 mm Hg and heart rate was
55 bpm. One patient with a history of AF was prescribed a combination of verapa-
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Table I. Baseline demographic and clinical characteristics of elderly hospitalized
Australian patients with a diagnosis of atrial fibrillation (AF) and congestive
heart failure.
History of
All Patients AF Group AF Group
Variable (N = 140) (n = 92) (n = 48) P
Age, mean (SO), y 77.1 (6.9) 77.4 (9.2) 76.3 (12.4) NS
Sex, no. (%)
Male 74 (52.9) 45 (48.9) 29 (60.4) NS
Female 66 (47.1) 47 (51.1) 19 (39.6) NS
Hospitalization, mean (SO), d 6.4 (5.2) 6.8 (6.9) 5.1 (5.0) NS
Comorbidities, no. (%)
MI 54 (38.6) 33 (35.9) 21 (43.8) NS
CABG 32 (22.9) 22 (23.9) 10 (20.8) NS
Hypertension 79 (56.4) 53 (57.6) 26 (54.2) NS
Oiabetes 34 (24.3) 22 (23.9) 12 (25.0) NS
Oyslipidemia 34 (24.3) 23 (25.0) 11 (22.9) NS
Valvular heart disease 25 (17.9) 14 (15.2) 11 (22.9) NS
OCM 15 (10.7) 8 (8.7) 7 (14.6) NS
COPO 50 (35.7) 29 (31.5) 21 (43.8) NS
Stroke/TIA 19 (13.6) 15 (16.3) 4 (8.3) NS
Heart rate, mean (SO), bpm 91 (27) 97 (28) 71 (14) <0.01
SBP, mean (SO), mm Hg 134.4 (21.4) 133.3 (24.0) 136.5 (23.9) NS
OBP, mean (SO), mm Hg 74.6 (16.9) 76.2 (17.7) 71.6 (14.7) <0.01
HPT on admission, no. (%) 51 (36.4) 32 (34.8) 19 (39.6) NS
Left atrium, mean (SO), mm 51.9 (6.6) 51.8 (6.5) 52.3 (6.5) NS
LVEO, mean (SO), mm 53.7 (13.9) 51.0 (15.6) 54.8 (11.7) NS
LVEF, mean (SO), % 45.3 (21.2) 46.2 (20.0) 43.5 (18.7) NS
MI = myocardial infarction; CABG = coronary artery bypass graft; OCM = dilated cardiomyopathy; COPO=
chronic obstructive pulmonary disease; TIA = transient ischemic attack; SBP = systolic blood pressure;
OBP = diastolic blood pressure; HPT = hypertension; LVEO = left ventricular end diastolic; LVEF = left
ventricular ejection fraction.
mil and digoxin. He was also using betaxolol eye drops. At discharge his blood pres-
sure was 144/62 mm Hg and his EeG showed first-degree heart block and a heart rate
of 41 bpm.
VENTRICULAR RATE CONTROL
The mean (SD) resting heart rate for the 140 patients was 91 (27) bpm. The mean
resting heart rate for the patients with AF was significantly higher at admission
than at discharge (97 [28J vs 79 [l9J bpm; P < 0.01).
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Table II. Number (%) of elderly hospitalized Australian patients with a diagnosis of atrial
fibrillation (AF) and congestive heart failure receiving the most commonly pre-
scribed cardiovascular medications.
History of
All Patients AF Group AF Group
Variable (N = 140) (n = 92) (n = 48) P
ACEI/ARB 81 (57.9) 54 (58.7) 27 (56.3) NS
Digoxin 64 (45.8) 50 (54.3) 14 (29.2) <0.01
Statins 46 (32.9) 29 (31.5) 17 (35.4) NS
Aspirin 45 (32.1) 31 (33.7) 14 (29.2) NS
I3-Blockers 45 (32.1) 26 (28.3) 19 (39.6) NS
Amiodarone 26 (18.6) 7 (7.6) 19 (39.6) <0.01
Spironolactone 21 (15.0) 17 (18.5) 4 (8.3) <0.01
Clopidogrel 14 (10.0) 12 (13.0) 2 (4.2) NS
Heparin 12 (8.6) 10 (10.9) 2 (4.2) NS
Verapamil/diltiazem 12 (8.6) 9 (9.8) 3 (6.3) NS
Sotalol 6 (4.3) 2 (2.2) 4 (8.3) NS
Flecanide 1 (0.7) 1 (1.1) 0 NS
ACEI/ARB = angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker.
The percentage of the 140 patients who achieved the target heart rate of <80 bpm
on admission compared with at discharge was 46.2% (65) and 65.7% (92), respec-
tively (P < 0.01). A significantly smaller percentage of patients with continuous
AF achieved the target heart rate on admission than at discharge (33.7 % (3l} vs
60.9% [56]; P < 0.01).
At discharge, 12.1 % (17) of the 140 patients were receiving combination treat-
ment with f3-blockers and digoxin, including 12 patients from the continued AF
group. In the continued AF group, at discharge, a similar percentage of patients with
controlled and uncontrolled heart rate were receiving combination treatment with
f3-blockers and digoxin (12.5% (7/56) vs 13.9% [5/36}; P > 0.05).
ANTICOAGULATION TREATMENT
One hundred thirty-eight of the 140 study patients (98.6%) had ~2 moderate-risk
factors or ~1 high-risk factor for stroke. Among these patients, 28 (20.3%) either had
conrraindications for warfarin treatment or were treated with heparin at discharge
(Table III). Therefore, 110 patients (79.7%) were considered eligible for oral antico-
agulation treatment. Among these, 80 patients (72.7%) were in the AF group and
30 (27.3%) had a history of AF.
At discharge, 64 patients (58.2%) were prescribed warfarin. The prescription rate
was similar between patients with AF and those with a history of AF (55.0% [44) vs
66.6% [20}; P > 0.05). There was no significant difference in the percentage of pa-
tients in the warfarin and nonwarfarin groups (Table IV). However, eligible patients
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Table III. Reasons for exclusionfrom warfarin treatment In elderly
hospitalized Australian patients with a diagnosis of
atrial fibrillation and congestive heart failure.
Criterion
Heparin/LMWH prescribed
Peptic ulcer disease/leg ulcer
Peritoneal/hemodialysis
Soft tissue injuries from falls
Thrombocytopenia and coagulopathy
LMWH = low-molecular-weight heparin.
No. of Patients
12
10
2
2
2
not receiving oral warfarin were significantly older than those who did receive war-
farin (79.7 [9.0} vs 75.8 [9.0} years; P = 0.02). A significantly greater percentage of
patients in the nonwarfarin group than the warfarin group were aged ~75 years
(80.4% 07} vs 57.8% (37}; P = 0.01).
Of the 46 patients who were not prescribed warfarin, aspirin and clopidogrel were
prescribed for 27 (58.7%) and 7 (15.2%) patients, respectively. Twelve patients
(26.1 %) were not treated with either antiplatelet or anticoagulation agents.
DISCUSSION
Although there have been numerous publicarions<P on pharmacologic management
of AF in patients with or without CHF, there has been limited information on antiar-
rhythmic and anticoagulation treatment in elderly hospitalized patients with both AF
and CHF in Australia.
Out retrospective study in patients with AF and CHF found rate control improved
during hospitalization in these patients with continuous AF. The proportion of pa-
tients with a target resting heart rate « 80 bpm) increased from 33.7 % on admission
to 60.9% at discharge. However, approximately one third of the patients still had a
Table IV. Characteristics of elderly hospitalized Australian patients with a diagnosis of
atrial fibrillation and congestive heart failure eligible for warfarin treatment.
Warfarin
Not Prescribed Prescribed
Variable (n = 46) (n = 64) P
Age, mean (SD), y 79.7 (9.0) 75.8 (9.0) 0.02
Aged ~75 y, no. (%) 37 (80.4) 37 (57.8) 0.01
Aged ~85 y, no. (%) 15 (32.6) 11 (17.2) NS
Sex, no. (%)
Male 24 (52.2) 37 (57.8) NS
Female 22 (47.8) 27 (42.2) NS
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resting heart rate of >80 bpm at discharge. The reasons for the apparently suboptimal
heart rate control in these patients need to be further investigated.
Achieving heart rate control in our patients may have been complicated by the
presence of heart failure. AF and heart failure often coexist in the same patient because
they are closely relared.v Persistent or permanent AF compromises ventricular func-
tion because of the loss of atrioventricular synchrony and/or irregular, rapid ventricu-
lar response, which may lead to tachycardia-induced cardiomyopathy.' On the other
hand, CHF may increase atrial mass and/or pressure and cause neuroendocrine chang-
es, all of which may lead to AF. Indeed, the prevalence of AF in patients with heart
failure increases significantly as left ventricular dysfunction becomes more advanced.V
The prevalence of AF in the 417 patients whose hospital records were screened was
33.6%, which is consistent with the literature.
To achieve optimal heart rate control in patients with AF, a combination of ~2 rate
control drugs and frequent dose adjustment may be required.P One of these combina-
tion therapies, digoxin and l3-blockers, may be particularly important for heart rate
control during exercise.v' In the present study, the most commonly used individual
heart rate control medication was digoxin, followed by l3-blockers. It may be argued
that both drugs were prescribed for heart failure as well, since the specific therapeutic
purposes of the 2 drugs were difficult to ascertain in this retrospective analysis. In
patients with heart failure and reduced systolic function, the combination of digoxin
and a l3-blocker has been reported to reduce symptoms, improve ventricular function,
and lead to better rate control than either agent alone.24 In our study, however, 13.0%
of the patients in the continuous AF group were prescribed a combination of digoxin
and l3-blockers.
In this study, -10% of patients with continuous AF were being treated with vera-
pamil or diltiazem at discharge. Because all the patients were hospitalized due to
significant systolic ventricular dysfunction, verapamil and diltiazem should have been
used cautiously, since both agents depress myocardial contractility and may worsen
heart failure symptoms or prognosis. In fact, 2 patients who had bradycardia or heart
block were taking verapamil and a l3-blocker at discharge. The issue of bradycardia in
these patients could have been better addressed by adjusting the dose of verapamil or
l3-blocker at discharge. Also, 7.6% of our patients with continuous AF were treated
with amiodarone for heart rate control. Although amiodarone has not been reported
to increase the risk of death among heart failure patients with AF,25 it is associated
with a number of adverse effects (eg, pulmonary and thyroid toxicities) when used
long term." Therefore, whether amiodarone should be used for long-term heart rate
control for AF in patients with heart failure needs further study.
Despite the high risk of stroke in our patients and the fact that oral anticoagula-
tion treatment significantly reduces the risk of stroke,8-13 warfarin was used in ap-
proximately half of the eligible patients. The remaining patients were managed
largely with aspirin, which is less effective than warfarin in preventing stroke. 18
These results are comparable to the earlier studies26-28 but deviate from a recent
study.l? which reported higher anticoagulation prescription rates than any other
clinical trial.
521
CURRENT THERAPEUTIC RESEARCH
The reasons for the low anticoagulation treatment prescription rate in the present
study population are unclear. Previous studies have identified a number of patient-,
physician-, and health care system-related barriers to warfarin prescriprion.Yr''!
Although it is difficult to ascertain the specific barriers for warfarin prescription in our
study population, age seems to have been a key factor. Patients without a warfarin pre-
scription at discharge were generally older and were more likely to be aged> 75 years.
Whether other factors, such as patient treatment preference, access to blood tests for
therapeutic monitoring after discharge, and/or physicians' awareness of the current
therapeutic guidelines, contributed to the lower prescription rate of anticoagulation
treatment warrants further investigation.
LIMITATIONS
The participants in this study were taken from a small subset of hospitalized
patients with worsening heart failure. The results of this study largely reflect the level
of care of hospitalized patients with heart failure; they mayor may not be indicative
of the management of AF in the outpatient setting. Although the presence of AF was
determined based on intermittent ECG readings during hospitalization, the diagnosis
was confirmed by patients' ECG and medical history prior to hospitalization.
CONCLUSIONS
In these elderly hospitalized Australian patients with AF and CHF, digoxin,
/3-blockers, and amiodarone were the most commonly used antiarrhythmic drugs.
Anticoagulation treatment was prescribed in -60% of these patients. The reasons why
warfarin was not prescribed more frequently remain unclear, but older age appeared
to be one of the contributing factors.
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